MXPA05008879A - Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral. - Google Patents

Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral.

Info

Publication number
MXPA05008879A
MXPA05008879A MXPA05008879A MXPA05008879A MXPA05008879A MX PA05008879 A MXPA05008879 A MX PA05008879A MX PA05008879 A MXPA05008879 A MX PA05008879A MX PA05008879 A MXPA05008879 A MX PA05008879A MX PA05008879 A MXPA05008879 A MX PA05008879A
Authority
MX
Mexico
Prior art keywords
antitumor agent
combined therapy
another antitumor
indolopyrrolocarbazole derivative
indolopyrrolocarbazole
Prior art date
Application number
MXPA05008879A
Other languages
English (en)
Spanish (es)
Inventor
Enrico Pesenti
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of MXPA05008879A publication Critical patent/MXPA05008879A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
MXPA05008879A 2003-02-21 2004-02-16 Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral. MXPA05008879A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000317A ITMI20030317A1 (it) 2003-02-21 2003-02-21 Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
PCT/EP2004/050130 WO2004073719A1 (fr) 2003-02-21 2004-02-16 Traitement combine comprenant un derive d'indolopyrrolocarbazole et un autre agent antitumoral

Publications (1)

Publication Number Publication Date
MXPA05008879A true MXPA05008879A (es) 2005-10-05

Family

ID=32894164

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008879A MXPA05008879A (es) 2003-02-21 2004-02-16 Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral.

Country Status (10)

Country Link
EP (1) EP1599210A1 (fr)
JP (1) JP2006518355A (fr)
AR (1) AR043241A1 (fr)
BR (1) BRPI0407642A (fr)
CA (1) CA2516097A1 (fr)
CL (1) CL2004000319A1 (fr)
IT (1) ITMI20030317A1 (fr)
MX (1) MXPA05008879A (fr)
TW (1) TW200500073A (fr)
WO (1) WO2004073719A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007307080B2 (en) * 2006-10-06 2014-01-09 Bavarian Nordic A/S Methods for treating cancer with MVA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
EE200200471A (et) * 2000-02-28 2003-12-15 Aventis Pharma S.A. Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks

Also Published As

Publication number Publication date
ITMI20030317A1 (it) 2004-08-22
AR043241A1 (es) 2005-07-20
WO2004073719A1 (fr) 2004-09-02
BRPI0407642A (pt) 2006-03-01
EP1599210A1 (fr) 2005-11-30
TW200500073A (en) 2005-01-01
CA2516097A1 (fr) 2004-09-02
JP2006518355A (ja) 2006-08-10
CL2004000319A1 (es) 2005-04-22

Similar Documents

Publication Publication Date Title
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
WO2004093831A3 (fr) Combinaisons de vaccins cellulaires exprimant les cytokines
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
MX2007009960A (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
SG161307A1 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
HK1120441A1 (en) Drugs for treatment of ovarian cancer
HK1071310A1 (en) Combination therapy for the treatment of cancer
WO2004006842A3 (fr) Association de medicaments pour le traitement de tumeurs
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
WO2005025501A3 (fr) Co-administration de polysaccharide avec un agent chimiotherapeutique pour le traitement du cancer
NO20064753L (no) Kombinasjonsterapi
TW200608959A (en) Treatment with oxaliplatin and an egfr-inhibitor
MXPA05008879A (es) Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral.
MXPA04009012A (es) Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer.
WO2002076393A3 (fr) Agents antiangionenes, antitumoraux, et chimiopreventifs
TW200509925A (en) Method comprising irinotecan for treatment of breast cancer
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
MXPA05013827A (es) Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g.
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
WO2003032895A3 (fr) Methodes et compositions pharmaceutiques destinees a la stimulation du systeme immunitaire et/ou au traitement du cancer